Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | VEGFA | P15692 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493401 | 0.85 | ALDH1A1 (0.42) | KMT2AGSK3BRAB9ALMNASMN1; SMN2 | |
| SCHEMBL493603 | 0.82 | KMT2A (0.44) | MAPTKDM4EKMT2ATP53RXFP1 | |
| SCHEMBL493270 | 0.82 | TPMT (0.39) | TP53RXFP1RAB9ASMN1; SMN2 | |
| SCHEMBL492888 | 0.81 | SHMT1 (0.48) | CYP2C19MAPTKDM4EKMT2ARXFP1 | |
| SCHEMBL493024 | 0.80 | CYP2C19 (0.47) | CYP2C19MAPTKDM4EKMT2AEGLN1 | |
| SCHEMBL493104 | 0.74 | POLB (0.46) | KMT2AEGLN1GSK3BVEGFAFLT1 | |
| SCHEMBL493223 | 0.74 | RAB9A (0.38) | MAPTKDM4EKMT2ARAB9A | |
| SCHEMBL493438 | 0.71 | KMT2A (0.67) | MAPTKDM4EKMT2A | |
| SCHEMBL493476 | 0.70 | FABP4 (0.48) | MAPTKDM4EKMT2AGSK3BRAB9A | |
| SCHEMBL493052 | 0.69 | KDM4E (0.73) | CYP2C19MAPTKDM4EKMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | CYP2C19 134/4885MAPT 1653/4885KDM4E 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.